XASE
CYBN
Market cap181mUSD
Jul 07, Last price
7.87USD
1D
-0.88%
1Q
57.40%
IPO
304.50%
Name
Cybin Inc
Chart & Performance
Profile
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑07 | 2018‑07 | 2017‑07 | |
Income | ||||||||
Revenues | ||||||||
Cost of revenue | 65,374 | 51,769 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (65,374) | (51,769) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (7,453) | |||||||
Tax Rate | ||||||||
NOPAT | (65,374) | (44,316) | ||||||
Net income | (78,080) 95.02% | (40,037) -43.94% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 254,600 | 31,507 | ||||||
BB yield | ||||||||
Debt | ||||||||
Debt current | ||||||||
Long-term debt | 291 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | 5,262 | |||||||
Net debt | (208,701) | (53,883) | ||||||
Cash flow | ||||||||
Cash from operating activities | (68,908) | (45,207) | ||||||
CAPEX | (21) | (520) | ||||||
Cash from investing activities | 6,922 | (770) | ||||||
Cash from financing activities | 254,507 | 35,777 | ||||||
FCF | (65,430) | (44,250) | ||||||
Balance | ||||||||
Cash | 208,992 | 53,641 | ||||||
Long term investments | 242 | |||||||
Excess cash | 208,992 | 53,883 | ||||||
Stockholders' equity | 280,177 | 40,424 | ||||||
Invested Capital | 82,935 | 35,731 | ||||||
ROIC | ||||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 8,299 | 185,429 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (64,950) | (51,601) | ||||||
EV/EBITDA | ||||||||
Interest | 7,453 | |||||||
Interest/NOPBT |